51
|
Cheng J, Ho C, Honney K, Wells M, Wise W, Ferguson N, Bailey S, May H, Burridge R. 28 Can Comprehensive Geriatric Assessment be Achieved in the Emergency Department? Age Ageing 2020. [DOI: 10.1093/ageing/afz183.28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Our National Health Service is facing unprecedented challenges to accommodate our frailer healthcare users. The gold standard tool for the identification and management of frailty is the Comprehensive Geriatric Assessment (CGA) and has been shown to lead to better outcomes in terms of morbidity and mortality.
Introduction
With a largely elderly demographic profile in the East of England, the Norfolk and Norwich University Hospital opened the first Older People’s Emergency Department (OPED) in the UK in 2017. This work reviews the effectiveness of a geriatrician-led CGA in a dedicated OPED, which operates during daylight hours, compared to usual care in Accident & Emergency (A&E).
Methods
99 patients assessed in OPED and 99 patients assessed overnight in A&E during February 2019 were included in this retrospective study. Electronic case notes for each patient were reviewed by the authors and results were expressed as percentages.
Results
OPED outperformed A&E in all components of the CGA; strongest areas included assessing for pain, falls risk and activities of daily living. Both departments performed well in reviewing medications and assessing for safeguarding concerns. Areas for improvement include assessing for mood disorders, sensory impairment, discussing Do Not Attempt Cardiopulmonary Resuscitation status, and end of life care plans. The average length of stay of OPED patients was only 7.3 days compared to 8.7 days in A&E, and 89% of OPED patients were discharged back to their usual residences compared to 87% in A&E.
Conclusions
The improved CGA process in OPED has led to better outcomes, notably through a reduction in the average length of inpatient stay. Nevertheless, certain components of the CGA still require improvement. Further examination is needed to assess long-term mortality to support the use of CGA in the emergency setting.
Collapse
Affiliation(s)
- J Cheng
- Norfolk and Norwich University Hospital NHS Foundation Trust, United Kingdom
| | - C Ho
- Norfolk and Norwich University Hospital NHS Foundation Trust, United Kingdom
| | - K Honney
- Norfolk and Norwich University Hospital NHS Foundation Trust, United Kingdom
| | - M Wells
- Norfolk and Norwich University Hospital NHS Foundation Trust, United Kingdom
| | - W Wise
- Norfolk and Norwich University Hospital NHS Foundation Trust, United Kingdom
| | - N Ferguson
- Norfolk and Norwich University Hospital NHS Foundation Trust, United Kingdom
| | - S Bailey
- Norfolk and Norwich University Hospital NHS Foundation Trust, United Kingdom
| | - H May
- Norfolk and Norwich University Hospital NHS Foundation Trust, United Kingdom
| | - R Burridge
- Norfolk and Norwich University Hospital NHS Foundation Trust, United Kingdom
| |
Collapse
|
52
|
Chu Q, Agha A, Devost N, Walton RN, Ghosh S, Ho C. Biopsy on progression in patients with EGFR mutation-positive advanced non-small-cell lung cancer-a Canadian experience. ACTA ACUST UNITED AC 2020; 27:27-33. [PMID: 32218657 DOI: 10.3747/co.27.5347] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Background Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors (tkis) are standard therapy for patients with advanced or metastatic non-small-cell lung cancer harbouring an EGFR mutation. Upon progression, 50%-60% develop a secondary T790M mutation. Recent trials demonstrated outcome improvement with osimertinib compared with standard platinum-based chemotherapy as second-line therapy for patients with secondary T790M mutation. To identify T790M, a biopsy of the tumour or, more recently, plasma is necessary. This retrospective study aimed to evaluate biopsy procedures and mutational analysis at 2 Canadian cancer centres. Methods In a retrospective review of patients who were approached to enrol in the aura2, aura3, or astris studies, demographics, eligibility for rebiopsy upon progression after an egfr tki, rebiopsy methods and complications, number of rebiopsies, and incidence of the T790M mutation were collected. Results Of 84 patients considered for trial enrolment, 80 signed a consent. In 78 patients who underwent rebiopsy, computed tomography or ultrasonography guidance were the most common methods used. The most common biopsy sites were lung and lymph nodes. The median number of rebiopsies performed to find a T790M mutation was 2. Only 9% of patients experienced complications. Of samples obtained, 74% were adequate for testing after initial rebiopsy. A T790M mutation was found in 47 patients, of whom 44 were enrolled on a trial. After multiple rebiopsies, only 5% of samples were inadequate for molecular analysis. Conclusions In the Canadian setting, the acceptance of rebiopsy on progression was high. Multiple rebiopsies were clinically feasible and could increase the yield for T790M mutation. The incidence of complications was low despite the most common site for rebiopsy being lung.
Collapse
Affiliation(s)
- Q Chu
- Cross Cancer Institute, Alberta Health Services, Edmonton, AB
| | - A Agha
- BC Cancer-Vancouver Centre, Vancouver, BC
| | - N Devost
- AstraZeneca Canada, Mississauga, ON
| | | | - S Ghosh
- Cross Cancer Institute, Alberta Health Services, Edmonton, AB
| | - C Ho
- BC Cancer-Vancouver Centre, Vancouver, BC
| |
Collapse
|
53
|
Ho C, Chang C, Wong B. 782 Acute Coronary Syndrome in Severe Chronic Kidney Disease – Analysis of Management and Outcome. Heart Lung Circ 2020. [DOI: 10.1016/j.hlc.2020.09.789] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
54
|
Wong B, Thein A, Lee K, Ho C, Armstrong G, El-Jack S, To A. 842 Incidence, Predictors and Prognostic Impact of Patient-Prosthesis Mismatch Following Transcatheter Aortic Valve Implantation. Heart Lung Circ 2020. [DOI: 10.1016/j.hlc.2020.09.849] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
55
|
Wong B, Lee K, Thein A, Ho C, Armstrong G, El-Jack S. 856 Mid-Term Outcomes of Transcatheter Aortic Valve Implantation for Severe Aortic Stenosis: The Auckland Region Experience 2011-2016. Heart Lung Circ 2020. [DOI: 10.1016/j.hlc.2020.09.863] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
56
|
Ho C, Lee PH, So TC, Chiang MCS, Wong MH, Fong YH, Tsang CF, Cheng YW, Luk NH, Chui SF, Chan KC, Wong CY, Fu CL, Lee KY, Chan KT. 224 Malignancy associated pericardial effusion- do we need to drain them all? Eur Heart J 2020. [DOI: 10.1093/ehjci/ehz872.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
On Behalf
Cardiac Team, Department of Medicine, Queen Elizabeth Hospital
Background
Management of significant pericardial effusion in cancer patients is controversial. These patients have poor prognosis, and avoiding unnecessary intervention is important. Close monitoring of symptoms and echocardiogram is often a reasonable option, but inherits risk of cardiac tamponade. Whether pericardial drainage by means of percutaneous pericardiocentesis or surgical pericardiotomy could prevent future deterioration or affect survival is unknown.
Purpose
To evaluate the benefit of elective pericardial drainage in malignancy associated pericardial effusion without echocardiographic or clinical evidence of tamponade effect.
Methods
From 1st Jul 2014 to 31st Dec 2017, all patients with new onset malignancy-associated pericardial effusion with size more than 1cm were retrospectively analyzed. Patients with clinical or echocardiographic evidence of cardiac tamponade were excluded. We compared pericardial drainage versus monitoring for short-term (30-day), mid-term (90-day) and long term (1 year) survival without need for drainage.
Results
101 patients were retrospectively analyzed. 40 (39.6%) patients underwent drainage. Overall median survival free from drainage was 4 months. There were no significant difference in short-term (30-day), mid-term (90-day) and long term (1-year) survival free from drainage or mortality between treatment and monitoring group. Size of pericardial effusion did not predict mortality or future need of drainage. Chemotherapy was associated with improved 30-day mortality (RR 0.53 CI 0.32-0.87 p = 0.025) but not survival free from drainage or longer term mortality.
Conclusion
Close monitoring could be a feasible strategy in cancer patients with significant pericardial effusion without tamponade effect.
Baseline characteristics Factor Drainage (n = 40) monitoring (n = 61) p-value method of drainage pericardiocentesis alone 17 NA pericardiotomy alone 13 both 10 Male 19 (47.5%) 27 (44.3%) 0.749 mean size (cm) 1.93 2.77 <0.001 mean age 60.9 63.1 0.357 on chemotherapy 27 (67.5%) 38 (62.3%) 0.593
Abstract 224 Figure. Survival free from drainage
Collapse
Affiliation(s)
- C Ho
- Queen Elizabeth Hospital, Hong Kong, Hong Kong
| | - P H Lee
- Queen Elizabeth Hospital, Hong Kong, Hong Kong
| | - T C So
- Queen Elizabeth Hospital, Hong Kong, Hong Kong
| | | | - M H Wong
- Queen Elizabeth Hospital, Hong Kong, Hong Kong
| | - Y H Fong
- Queen Elizabeth Hospital, Hong Kong, Hong Kong
| | - C F Tsang
- Queen Elizabeth Hospital, Hong Kong, Hong Kong
| | - Y W Cheng
- Queen Elizabeth Hospital, Hong Kong, Hong Kong
| | - N H Luk
- Queen Elizabeth Hospital, Hong Kong, Hong Kong
| | - S F Chui
- Queen Elizabeth Hospital, Hong Kong, Hong Kong
| | - K C Chan
- Queen Elizabeth Hospital, Hong Kong, Hong Kong
| | - C Y Wong
- Queen Elizabeth Hospital, Hong Kong, Hong Kong
| | - C L Fu
- Queen Elizabeth Hospital, Hong Kong, Hong Kong
| | - K Y Lee
- Queen Elizabeth Hospital, Hong Kong, Hong Kong
| | - K T Chan
- Queen Elizabeth Hospital, Hong Kong, Hong Kong
| |
Collapse
|
57
|
Fan KYY, Wong KL, Fu N, Cheng KY, Chow YM, Au KL, Au WK, Ho C. P101 Cardiac rehabilitation program for end-stage heart failure patients with left ventricular assist devices in Hong Kong. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehz872.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Implantation of modern durable left ventricular assist device (LVAD) in advanced heart failure (HF) patients is associated with increased survival and improved quality of life. Exercise-based cardiac rehabilitation (EBCR) has been demonstrated to exercise capacity in HF patients but data on effect of EBCR in advanced HF patients with LVAD are limited.
Objectives
To evaluate the effect of EBCR program on the functional capacity of advanced heart failure patients with LVAD
Methods
Out of the current 64 LVAD recipients in Hong Kong, 43 patients who have had LVAD implanted and survived 1 year were screened. The EBCRP consisted of cardiorespiratory and strength training exercise once a week for a total of 24 sessions (6 months). The functional rehabilitation outcome was evaluated by 6 minute walk test (6MWT) at baseline, before LVAD implantation, pre-EBCR and by end of EBCP ( 6 months). The muscle strength was evaluated by an isokinetic knee extension strength test defined by 10 repetitive maximum (RM) torque of quadriceps strength before starting EBCR and at 6 months upon termination of EBCR.
Results
A total of 33 LVAD patients were recruited into our EBCR program. There were 27 (82%) men with mean age of 48.7± 13.6 years. Average duration from LVAD surgery to commencement of EBCR was 5.3 months. Baseline 6MWT could not be performed in 21 patients due to extreme poor functional class (NYHA class IV) with prolonged hospitalizations requiring inotropes and circulatory support. For the other 12 patients, there were no significant differences in 6 MWT at baseline and post LVAD before starting EBCP. Overall 6MWT significantly improved by end of EBCR (pre- EBCR mean 382.2, ±95.2m vs post -EBCR mean 440.8 ±88.2m p= 0.001). There were significant improvement in quadriceps strength by the end of EBCRP program. (pre- CRP 1.8 ± 2.5 kg vs post CRP 3.5 ± 3.5 kg p < 0.001).
Conclusions
LVAD patients show high level of impairment of functional capacity despite after LVAD imaplntation with improved circulatory output. EBCR program allowed greater improvement in exercise capacity evolution and peripheral physiology such as muscle strengthening.
Collapse
Affiliation(s)
- K Y Y Fan
- Grantham Hospital, Cardiac Medical Unit, Aberdeen, Hong Kong
| | - K L Wong
- Grantham Hospital, Cardiac Medical Unit, Aberdeen, Hong Kong
| | - N Fu
- Grantham Hospital, Cardiac Medical Unit, Aberdeen, Hong Kong
| | - K Y Cheng
- Grantham Hospital, Cardiac Medical Unit, Aberdeen, Hong Kong
| | - Y M Chow
- Grantham Hospital, Cardiac Medical Unit, Aberdeen, Hong Kong
| | - K L Au
- Grantham Hospital, Cardiac Medical Unit, Aberdeen, Hong Kong
| | - W K Au
- Queen Mary Hospital, Cardiothoracic Surgery Department, Hong Kong, Hong Kong
| | - C Ho
- Queen Mary Hospital, Cardiothoracic Surgery Department, Hong Kong, Hong Kong
| |
Collapse
|
58
|
Kwan S, Wong C, Ho C, Zhang Y, Tse T, Lau YM, Leung L, Tan T, Loong H. Neutrophil-lymphocyte and platelet-lymphocyte ratios as robust prognostic markers in sarcomas: A population-based analysis of 3746 sarcoma patients from Hong Kong. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz433.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
59
|
Wong S, Hamm J, Shokoohi A, Mcgahan C, Ho C. Curative treatment timelines for breast, colorectal, lung and prostate cancer: Implications for medical leave coverage. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz263.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
60
|
Liao B, Hsu W, Lee J, Yang C, Tsai T, Liao W, Ho C, Lin C, Shih J, Yu C, Yang J. P2.01-39 Serial Plasma ctDNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in T790M+ NSCLC. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1383] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
61
|
Su S, Ho H, Chen H, Ho C, Li K. P1.03-21 Epigenome-Wide Association Study of Cancer Associated Fibroblasts-Induced Oncogenic Transformation of Lung Epithelial Cells. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.873] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
62
|
Moore S, Leung B, Wu J, Ho C. P1.18-08 Survival Outcomes of Salvage Therapy for Locoregionally Recurrent Non-Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1324] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
63
|
Wu Y, Tu H, Feng J, Shi M, Zhao J, Wang Y, Chang J, Wang J, Cheng Y, Zhu J, Tan E, Zhang Y, Lee V, Yang C, Su W, Lam D, Srinivasa B, Rajappa S, Ho C, Lam K, Hu Y, Bondarde S, Liu X, Pang K, Tian Y, Cseh A, Huang D, Zhou C. P2.01-99 A Phase IIIb Open-Label Study of Afatinib in EGFR TKI-Naïve Patients with EGFR Mutation-Positive NSCLC: Final Analysis. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1442] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
64
|
Cheema P, Evans W, Burkes R, Sangha R, Ho C, Wheatley-Price P, Boehm D, Venkatesh J, Walisser S, Grima D, Moldaver D, Hurry M. Estimating the cost and survival impact of new aNSCLC therapies in Canada with the iTEN model. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
65
|
Pender A, Hughesman C, Law E, Kristanti A, Mcneil K, Tucker T, Bosdet I, Young S, Laskin J, Karsan A, Yip S, Ho C. P1.01-40 EGFR ctDNA Detection: The Impact of Site of Progression and Burden of Progressive Disease. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.755] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
66
|
Smrke A, Leung B, Bates A, Srikanthan A, Ho C. Psychosocial distress of adolescent and young adults with cancer at diagnosis: A case-matched retrospective cohort of 2045 patients in British Columbia. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz265.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
67
|
Pender A, Dunne EM, Wong SK, Ho C, Melosky B. Canadian Lung Cancer Conference 2019. Curr Oncol 2019; 26:e578-e580. [PMID: 31548828 DOI: 10.3747/co.26.5105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
The 19th Canadian Lung Cancer Conference took place 7-8 February 2019 in Vancouver, British Columbia. This annual interdisciplinary education event attracted participants from throughout Canada to review the latest advances in lung cancer care and to learn from world-renowned experts in the field. The highlights of this year's conference were perspectives about biomarkers for immunotherapy, approaches to oligoprogressive disease, and caregiver burnout.
Collapse
Affiliation(s)
- A Pender
- Medical Oncology, BC Cancer, Vancouver, BC
| | - E M Dunne
- Radiation Oncology, BC Cancer, Vancouver, BC
| | - S K Wong
- Medical Oncology, BC Cancer, Vancouver, BC
| | - C Ho
- Medical Oncology, BC Cancer, Vancouver, BC
| | - B Melosky
- Medical Oncology, BC Cancer, Vancouver, BC
| |
Collapse
|
68
|
Kiang JG, Smith JT, Anderson MN, Umali MV, Ho C, Zhai M, Lin B, Jiang S. A novel therapy, using Ghrelin with pegylated G-CSF, inhibits brain hemorrhage from ionizing radiation or combined radiation injury. Pharm Pharmacol Int J 2019; 7:133-145. [PMID: 34368440 PMCID: PMC8341084 DOI: 10.15406/ppij.2019.07.00243] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Medical treatment becomes challenging when complicated injuries arise from secondary reactive metabolic and inflammatory products induced by initial acute ionizing radiation injury (RI) or when combined with subsequent trauma insult(s) (CI). With such detrimental effects on many organs, CI exacerbates the severity of primary injuries and decreases survival. Previously, in a novel study, we reported that ghrelin therapy significantly improved survival after CI. This study aimed to investigate whether brain hemorrhage induced by RI and CI could be inhibited by ghrelin therapy with pegylated G-CSF (i.e., Neulasta®, an FDA-approved drug). B6D2F1 female mice were exposed to 9.5 Gy 60Co-γ-radiation followed by 15% total-skin surface wound. Several endpoints were measured at several days. Brain hemorrhage and platelet depletion were observed in RI and CI mice. Brain hemorrhage severity was significantly higher in CI mice than in RI mice. Ghrelin therapy with pegylated G-CSF reduced the severity in brains of both RI and CI mice. RI and CI did not alter PARP and NF-κB but did significantly reduce PGC-1α and ghrelin receptors; the therapy, however, was able to partially recover ghrelin receptors. RI and CI significantly increased IL-6, KC, Eotaxin, G-CSF, MIP-2, MCP-1, MIP-1α, but significantly decreased IL-2, IL-9, IL-10, MIG, IFN-γ, and PDGF-bb; the therapy inhibited these changes. RI and CI significantly reduced platelet numbers, cellular ATP levels, NRF1/2, and AKT phosphorylation. The therapy significantly mitigated these CI-induced changes and reduced p53-mdm2 mediated caspase-3 activation. Our data are the first to support the view that Ghrelin therapy with pegylated G-CSF is potentially a novel therapy for treating brain hemorrhage after RI and CI.
Collapse
Affiliation(s)
- J G Kiang
- Radiation Combined Injury Program, Scientific Research Department, Armed Forces Radiobiology Research Institute, USA
- Department of Medicine, Uniformed Services University of the Health Sciences, USA
- Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, USA
| | - J T Smith
- Radiation Combined Injury Program, Scientific Research Department, Armed Forces Radiobiology Research Institute, USA
| | - M N Anderson
- Radiation Combined Injury Program, Scientific Research Department, Armed Forces Radiobiology Research Institute, USA
| | - M V Umali
- Radiation Combined Injury Program, Scientific Research Department, Armed Forces Radiobiology Research Institute, USA
| | - C Ho
- Department of Biochemistry, University of California, USA
| | - M Zhai
- Radiation Combined Injury Program, Scientific Research Department, Armed Forces Radiobiology Research Institute, USA
| | - B Lin
- Radiation Combined Injury Program, Scientific Research Department, Armed Forces Radiobiology Research Institute, USA
| | - S Jiang
- Radiation Combined Injury Program, Scientific Research Department, Armed Forces Radiobiology Research Institute, USA
| |
Collapse
|
69
|
Ho C, Trinh T, Nguyen A, Nguyen Q, Ercan A, Kavvas ML. Reconstruction and evaluation of changes in hydrologic conditions over a transboundary region by a regional climate model coupled with a physically-based hydrology model: Application to Thao river watershed. Sci Total Environ 2019; 668:768-779. [PMID: 30865907 DOI: 10.1016/j.scitotenv.2019.02.368] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/12/2018] [Revised: 02/04/2019] [Accepted: 02/24/2019] [Indexed: 06/09/2023]
Abstract
The differences among countries in terms of physical features, governmental policies, priorities in short- and long-term water resources management may lead to conflicts in managing and sharing of water resources over the transboundary regions. Due to no formal data sharing agreement between countries, there has been usually no data availability at transboundary regions. In this study, a methodology, in which a physically-based hydrology model was coupled with a regional climate model, is proposed to reconstruct and evaluate hydrologic conditions over transboundary regions. For the case study, Thao river watershed (TRW), within Vietnam and China, was selected. The Watershed Environmental Hydrology (WEHY) model was implemented based on topography, soil, and land use/cover information which was retrieved from global satellite data resources. The watershed model-WEHY was first validated over the TRW, and then was used to reconstruct historical hydrologic conditions during 1950-2007. The results of this study suggest no significant trend in the annual streamflow over the target watershed. In addition, there is a time shift in the wet season between the upstream sector in China and the downstream sector in Vietnam over the TRW. The annual flow contribution from the upstream sector in China to the outlet of TRW is estimated to be around 66%, and the remaining 34% contribution comes from the downstream sector in Vietnam territory. Last but not the least, the annual flow as a function of return period varies not only with the return period but also as a function of the time window, reflecting the effect of the changing regime on the streamflows at the TRW. The evolution of the flow frequency through time is an evidence of the ongoing non-stationarity in the hydrologic conditions over TRW.
Collapse
Affiliation(s)
- C Ho
- The Key Laboratory of River and Coastal Engineering, Viet Nam.
| | - T Trinh
- Faculty of Hydrology and Water Resources, Thuy loi University, Viet Nam; Hydrologic Research Laboratory, Dept. of Civil and Environmental Engineering, Univ. of California, Davis, CA, United States of America.
| | - A Nguyen
- Hydrologic Research Laboratory, Dept. of Civil and Environmental Engineering, Univ. of California, Davis, CA, United States of America.
| | - Q Nguyen
- The Key Laboratory of River and Coastal Engineering, Viet Nam
| | - A Ercan
- J. Amorocho Hydraulics Laboratory, Dept. of Civil and Environmental Engineering, Univ. of California, Davis, CA, United States of America.
| | - M L Kavvas
- Hydrologic Research Laboratory, Dept. of Civil and Environmental Engineering, Univ. of California, Davis, CA, United States of America.
| |
Collapse
|
70
|
Sauter C, Lin R, Ho C, Devlin S, Maloy M, Perales M, Dahi P, Schoder H, Jakubowski A, Barker J, Papadopoulos E, Giralt S. ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IMPACTS ON IMMUNE EVASIVE MECHANISMS IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA - A SINGLE CENTER EXPERIENCE. Hematol Oncol 2019. [DOI: 10.1002/hon.113_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- C.S. Sauter
- Medicine; Adult BMT Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - R.J. Lin
- Medicine; Adult BMT Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - C. Ho
- Medicine; Adult BMT Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - S.M. Devlin
- Medicine; Adult BMT Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - M.A. Maloy
- Medicine; Adult BMT Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - M. Perales
- Medicine; Adult BMT Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - P.B. Dahi
- Medicine; Adult BMT Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - H. Schoder
- Medicine; Adult BMT Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - A.A. Jakubowski
- Medicine; Adult BMT Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - J.N. Barker
- Medicine; Adult BMT Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - E.B. Papadopoulos
- Medicine; Adult BMT Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - S.A. Giralt
- Medicine; Adult BMT Service, Memorial Sloan Kettering Cancer Center; New York United States
| |
Collapse
|
71
|
Ho C, Chen Y, Ho S, Chen H, Chien C, Chen J, Hsiao C, Chen H, Hu R, Shih D, Lee P. CD34+ stromal vascular fraction was instrumental in mediating hepatic repair regarding gene expression profiles. Cytotherapy 2019. [DOI: 10.1016/j.jcyt.2019.04.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
72
|
Lee H, Tsai J, Chen S, Lai I, Chen C, Ho C, Chiou J, Kuo Y. EP-1355 Oligo-progressive status exhibits unfavorable survival in pulmonary oligo-recurrence treated by SABR. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31775-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
73
|
Wang X, Ho C, Tsatskis Y, Law J, Zhang Z, Zhu M, Dai C, Wang F, Tan M, Hopyan S, McNeill H, Sun Y. Intracellular manipulation and measurement with multipole magnetic tweezers. Sci Robot 2019; 4:4/28/eaav6180. [DOI: 10.1126/scirobotics.aav6180] [Citation(s) in RCA: 75] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2018] [Accepted: 01/16/2019] [Indexed: 12/15/2022]
Abstract
The capability to directly interrogate intracellular structures inside a single cell for measurement and manipulation is important for understanding subcellular and suborganelle activities, diagnosing diseases, and developing new therapeutic approaches. Compared with measurements of single cells, physical measurement and manipulation of subcellular structures and organelles remain underexplored. To improve intracellular physical measurement and manipulation, we have developed a multipole magnetic tweezers system for micromanipulation involving submicrometer position control and piconewton force control of a submicrometer magnetic bead inside a single cell for measurement in different locations (spatial) and different time points (temporal). The bead was three-dimensionally positioned in the cell using a generalized predictive controller that addresses the control challenge caused by the low bandwidth of visual feedback from high-resolution confocal imaging. The average positioning error was quantified to be 0.4 μm, slightly larger than the Brownian motion–imposed constraint (0.31 μm). The system is also capable of applying a force up to 60 pN with a resolution of 4 pN for a period of time longer than 30 min. The measurement results revealed that significantly higher stiffness exists in the nucleus’ major axis than in the minor axis. This stiffness polarity is likely attributed to the aligned actin filament. We also showed that the nucleus stiffens upon the application of an intracellularly applied force, which can be attributed to the response of structural protein lamin A/C and the intracellular stress fiber actin filaments.
Collapse
|
74
|
Kwong A, Shin V, Au CH, Ho C, Slavin T, Weitzel J, Chan TL, Ma E. Abstract P5-09-12: Germline mutation in TP53 gene in a cohort of 2,561 Chinese high-risk breast cancer patients using multigene panel testing. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-09-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Li-Fraumeni syndrome (LFS) is a rare autosomal genetic disorder with germline TP53 mutations. Patients with TP53 mutations have a higher risk of developing breast cancer than those harboring BRCA mutations. Although limited studies have shown that TP53 mutation carriers are less responsive to low dose radiation and more susceptible to induce new malignancies from radiotherapy. Moreover screening strategies allows early detection of a spectrum of cancers related to TP53 mutations. From work of BRCA mutations where over 40% novel mutations were detected in Chinese cohort, it is important to evaluate the frequency of TP53 mutation in Chinese to better understand the spectrum to guide appropriate clinical management of these high risk individuals.
Methods: TP53 gene mutation screening was performed on 2,561 high-risk breast cancer patients using multigene panel testing. The patients were accrued by Hong Kong Hereditary and High Risk Breast Cancer Program from March 2007 to May 2018. All detected pathogenic mutations were further validated by bi-directional DNA sequencing and analyzed by our in-house developed bioinformatics pipeline.
Results: Sixteen distinct pathogenic or likely pathogenic variants were identified, and 3 of them were de novo TP53 mutations (18.75%). The mean age of patients who harbored TP53 mutation was 30.44 years (range 18-44), and 50% of the tumors were bilateral breast cancer. Of sixteen different pathogenic mutations, majority of them were missense mutation (87.5%), and 2 were nonsense mutation (12.5%). Four of the sixteen TP53 mutation carriers had family history of breast cancer, while others had a family history of lung cancer (43.75%).
Conclusion: This study revealed that seven patients were found to habor TP53 mutation even when they did not meet the criteria of LFS of LFS-like phenotype, implicated the importance of using multigene panel test for probands and their relatives to offer a comprehensive surveillance programe for TP53 carriers.
Citation Format: Kwong A, Shin V, Au CH, Ho C, Slavin T, Weitzel J, Chan TL, Ma E. Germline mutation in TP53 gene in a cohort of 2,561 Chinese high-risk breast cancer patients using multigene panel testing [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-09-12.
Collapse
Affiliation(s)
- A Kwong
- The University of Hong Kong, Pokfulam, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Shau Kei Wan, Hong Kong; Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong; City of Hope, Duarte, CA
| | - V Shin
- The University of Hong Kong, Pokfulam, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Shau Kei Wan, Hong Kong; Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong; City of Hope, Duarte, CA
| | - CH Au
- The University of Hong Kong, Pokfulam, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Shau Kei Wan, Hong Kong; Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong; City of Hope, Duarte, CA
| | - C Ho
- The University of Hong Kong, Pokfulam, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Shau Kei Wan, Hong Kong; Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong; City of Hope, Duarte, CA
| | - T Slavin
- The University of Hong Kong, Pokfulam, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Shau Kei Wan, Hong Kong; Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong; City of Hope, Duarte, CA
| | - J Weitzel
- The University of Hong Kong, Pokfulam, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Shau Kei Wan, Hong Kong; Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong; City of Hope, Duarte, CA
| | - TL Chan
- The University of Hong Kong, Pokfulam, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Shau Kei Wan, Hong Kong; Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong; City of Hope, Duarte, CA
| | - E Ma
- The University of Hong Kong, Pokfulam, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Shau Kei Wan, Hong Kong; Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong; City of Hope, Duarte, CA
| |
Collapse
|
75
|
Chu QC, Agha A, Devost N, Walton R, Ghosh S, Ho C. Biopsy on progression in EGFR mutation positive (EGFRm) advanced non-small cell lung cancer (aNSCLC) patients (pts): A Canadian experience. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
76
|
Leung B, Wu J, Laskin J, Rennie H, Bates A, Ho C. MA14.05 Social Isolation Increases Psychological Distress in Patients With NSCLC. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
77
|
Wu Y, Tu H, Feng J, Shi M, Zhao J, Wang Y, Chang J, Wang J, Cheng Y, Zhu J, Tan E, Li K, Zhang Y, Lee V, Yang C, Su W, Lam D, Srinivasa B, Rajappa S, Ho C, Lam K, Hu Y, Bondarde S, Liu X, Huang D, Wang Y, Pang K, Zhou C. P1.01-98 A Phase IIIb Trial of Afatinib in EGFRm+ NSCLC: Analyses of Outcomes in Patients with Brain Metastases or Dose Reductions. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.654] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
78
|
Chen H, Su S, Chen J, Chen H, Wu M, Ho C. P3.03-11 Lung Cancer Stem Cells on Immune Modulation in Tumorous Microenvironment. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1688] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
79
|
Kuo Y, Lin C, Ho C. P2.13-20 The Comparative Effectiveness of Gefitinib Versus Erlotinib on the Intracranial Progression-Free Survival in Patients with Brain Metastasis. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1415] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
80
|
Moore S, Ho C, Leung B, Wu J. P2.17-23 Optimal Therapy of Stage III NSCLC: The Role of Surgery in the Era of Immunotherapy. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1549] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
81
|
Cressman S, Peacock S, Tremblay A, Ho C, Tammemagi M, Lam S. P3.11-03 Implementing Lung Cancer Screening in Canada: Evidence on Adherence and Budget Impact from the Pan-Canadian Early Detection Study. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1799] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
82
|
Myers R, Brauer M, Ladhar S, Atkar-Khattra S, Yee J, Ho C, Mcguire A, Grant K, Lee A, Melosky B, Sun S, Tammemägi M, Lam S. OA09.07 Association Between Outdoor Air Pollution And Lung Cancer in Female Never Smokers. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.286] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
83
|
Ho C, Leung B, Rennie H, Laskin J, Wu J, Bates A. Patient reported stressors in the practical domain of a cancer diagnosis: The impact of socioeconomic status and geographic location. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy297.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
84
|
Ho C. MS26.02 Translation of Clinical Data to Real World - North America. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
85
|
Wu S, Liao W, Ho C, Shih J, Yu C. P1.15-33 Real-World Data on Prognostic Factors for Overall Survival in NSCLC Patients Treated with Bevacizumab Combination Therapy. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
86
|
Aisen P, Touchon J, Amariglio R, Andrieu S, Bateman R, Breitner J, Donohue M, Dunn B, Doody R, Fox N, Gauthier S, Grundman M, Hendrix S, Ho C, Isaac M, Raman R, Rosenberg P, Schindler R, Schneider L, Sperling R, Tariot P, Welsh-Bohmer K, Weiner M, Vellas B. EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials. J Prev Alzheimers Dis 2018; 4:116-124. [PMID: 29186281 DOI: 10.14283/jpad.2017.13] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
At a meeting of the EU/US/Clinical Trials in Alzheimer's Disease (CTAD) Task Force in December 2016, an international group of investigators from industry, academia, and regulatory agencies reviewed lessons learned from ongoing and planned prevention trials, which will help guide future clinical trials of AD treatments, particularly in the pre-clinical space. The Task Force discussed challenges that need to be addressed across all aspects of clinical trials, calling for innovation in recruitment and retention, infrastructure development, and the selection of outcome measures. While cognitive change provides a marker of disease progression across the disease continuum, there remains a need to identify the optimal assessment tools that provide clinically meaningful endpoints. Patient- and informant-reported assessments of cognition and function may be useful but present additional challenges. Imaging and other biomarkers are also essential to maximize the efficiency of and the information learned from clinical trials.
Collapse
Affiliation(s)
- P Aisen
- PPaul Aisen, Alzheimer's Therapeutic Research Institute (ATRI), Keck School of Medicine, University of Southern California, San Diego, CA, USA,
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
87
|
Dhanrajani P, Rynberg T, Ho C. Cone beam CT scan: Importance of CBCT in treatment plan. Br Dent J 2018; 225:464. [DOI: 10.1038/sj.bdj.2018.820] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
88
|
Neubauer S, Weintraub W, Appelbaum E, Desai M, Desvigne-Nickens P, Dimarco J, Dolman S, Ho C, Jerosch-Herold M, Kolm P, Kwong R, Maron M, Schulz-Menger J, Watkins H, Kramer C. P3165Baseline characteristics of the hypertrophic cardiomyopathy registry (n=2773). Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p3165] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- S Neubauer
- University of Oxford, Division of Cardiovascular Medicine, Oxford, United Kingdom
| | - W Weintraub
- Medstar Research Institute, Washington, United States of America
| | - E Appelbaum
- Harvard Medical School, Boston, United States of America
| | - M Desai
- Cleveland Clinic Foundation, Cleveland, United States of America
| | - P Desvigne-Nickens
- National Institutes of Health, NHLBI, Bethesda, United States of America
| | - J Dimarco
- University of Virginia, Charlottesville, United States of America
| | - S Dolman
- Medstar Research Institute, Washington, United States of America
| | - C Ho
- Harvard Medical School, Boston, United States of America
| | | | - P Kolm
- Medstar Research Institute, Washington, United States of America
| | - R Kwong
- Harvard Medical School, Boston, United States of America
| | - M Maron
- Harvard Medical School, Boston, United States of America
| | | | - H Watkins
- University of Oxford, Division of Cardiovascular Medicine, Oxford, United Kingdom
| | - C Kramer
- University of Virginia, Charlottesville, United States of America
| | | |
Collapse
|
89
|
Lau S, Wang Y, Ho C, Melosky B. Canadian Lung Cancer Conference 2018. Curr Oncol 2018. [DOI: 10.3747/co.25.4100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
The 2018 Canadian Lung Cancer Conference (CLCCO) took place 8–9 February in Vancouver, British Columbia. A highly anticipated event, the CLCCO attracts lung cancer professionals from across Canada to review the latest advances in lung cancer research in a multidisciplinary setting. It also brings world-renowned experts to share their knowledge. Some of the highlights this year included an overview of the remarkable advances in immuno-oncology, stereotactic radiotherapy, and navigational tools in bronchoscopy.
Collapse
|
90
|
Kuo T, Chen W, Ho C. Anomalous decrease in groundwater radon before 2016 Mw 6.4 Meinong earthquake and its application in Taiwan. Appl Radiat Isot 2018; 136:68-72. [DOI: 10.1016/j.apradiso.2018.02.015] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2016] [Revised: 01/04/2018] [Accepted: 02/14/2018] [Indexed: 11/28/2022]
|
91
|
Yuen C, Cherk W, Fung T, Ho C, Chan K, Yu Y. Melatonin versus chloral hydrate as the sedating agent in performing electroencephalogram in paediatric patients. ACTA ACUST UNITED AC 2018. [DOI: 10.1016/j.ijep.2016.11.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
AbstractElectroencephalography (EEG) is a valuable tool in the diagnosis of epilepsy. The attainment of a high quality EEG requires patient's co-operation which is particularly difficult in children. Chloral hydrate has been used as a sedating agent in EEGs but it has potential serious adverse effects and anti-epileptic activity. Melatonin is used increasingly in different investigations as a safe alternative. Our study is to compare their effectiveness as sedating agents in performing EEGs and the detection rate of abnormal EEGs. This is a retrospective study performed in a regional hospital in Hong Kong. One hundred and ninety two EEG studies were included from December 2010 to July 2014. One hundred and two children were given chloral hydrate (50 mg/Kg) in the first half of the period and 90 children were given melatonin (3 mg for =< 5 years or 6 mg for >= 5 year) in the later half. The two groups are compared with Pearson's Chi-squared test with Yates’ continuity correction. The successful rate in sedation was similar between the two groups while the pick up rate of abnormal EEGs was 52.56% in the melatonin group and 21.57% in the chloral hydrate group (p < 0.05). Subgroup analysis among patients with epilepsy or mental retardation and intellectual disability shared same findings with higher detection rate of abnormal EEGs in the melatonin group. No side effect was documented in the study. Compare with chloral hydrate, melatonin is a safe and effective alternative and probably has less interference with the electrographic activity.
Collapse
Affiliation(s)
- C. Yuen
- Department of Paediatrics, Kwong Wah Hospital, Hong Kong Special Administrative Region
| | - W. Cherk
- Department of Paediatrics, Kwong Wah Hospital, Hong Kong Special Administrative Region
| | - T. Fung
- Department of Paediatrics, Kwong Wah Hospital, Hong Kong Special Administrative Region
| | - C. Ho
- Department of Paediatrics, Kwong Wah Hospital, Hong Kong Special Administrative Region
| | - K. Chan
- Department of Paediatrics, Kwong Wah Hospital, Hong Kong Special Administrative Region
| | - Y. Yu
- Electrodiagnostic Unit, Kwong Wah Hospital, Hong Kong Special Administrative Region
| |
Collapse
|
92
|
Jones MR, Lim H, Shen Y, Pleasance E, Ch'ng C, Reisle C, Leelakumari S, Zhao C, Yip S, Ho J, Zhong E, Ng T, Ionescu D, Schaeffer DF, Mungall AJ, Mungall KL, Zhao Y, Moore RA, Ma Y, Chia S, Ho C, Renouf DJ, Gelmon K, Jones SJM, Marra MA, Laskin J. Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer. Ann Oncol 2018; 28:3092-3097. [PMID: 28950338 DOI: 10.1093/annonc/mdx523] [Citation(s) in RCA: 72] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Background NRG1 fusion-positive lung cancers have emerged as potentially actionable events in lung cancer, but clinical support is currently limited and no evidence of efficacy of this approach in cancers beyond lung has been shown. Patients and methods Here, we describe two patients with advanced cancers refractory to standard therapies. Patient 1 had lung adenocarcinoma and patient 2 cholangiocarcinoma. Whole-genome and transcriptome sequencing were carried out for these cases with select findings validated by fluorescence in situ hybridization. Results Both tumors were found to be positive for NRG1 gene fusions. In patient 1, an SDC4-NRG1 gene fusion was detected, similar gene fusions having been described in lung cancers previously. In patient 2, a novel ATP1B1-NRG1 gene fusion was detected. Cholangiocarcinoma is not a disease type in which NRG1 fusions had been described previously. Integrative genome analysis was used to assess the potential functional significance of the detected genomic events including the gene fusions, prioritizing therapeutic strategies targeting the HER-family of growth factor receptors. Both patients were treated with the pan HER-family kinase inhibitor afatinib and both displayed significant and durable response to treatment. Upon progression sites of disease were sequenced. The lack of obvious genomic events to describe the disease progression indicated that broad transcriptomic or epigenetic mechanisms could be attributed to the lack of prolonged response to afatinib. Conclusion These observations lend further support to the use of pan HER-tyrosine kinase inhibitors for the treatment of NRG1 fusion-positive in both cancers of lung and hepatocellular origin and indicate more broadly that cancers found to be NRG1 fusion-positive may benefit from such a clinical approach regardless of their site of origin. Clinical trial information Personalized Oncogenomics (POG) Program of British Columbia: Utilization of Genomic Analysis to Better Understand Tumour Heterogeneity and Evolution (NCT02155621).
Collapse
Affiliation(s)
- M R Jones
- Canada's Michael Smith Genome Sciences Centre
| | - H Lim
- Division of Medical Oncology, BC Cancer Agency, Vancouver
| | - Y Shen
- Canada's Michael Smith Genome Sciences Centre
| | - E Pleasance
- Canada's Michael Smith Genome Sciences Centre
| | - C Ch'ng
- Canada's Michael Smith Genome Sciences Centre
| | - C Reisle
- Canada's Michael Smith Genome Sciences Centre
| | | | - C Zhao
- Canada's Michael Smith Genome Sciences Centre
| | - S Yip
- Department of Pathology & Laboratory Medicine, Vancouver General Hospital, Vancouver
| | - J Ho
- Department of Pathology & Laboratory Medicine, Vancouver General Hospital, Vancouver
| | - E Zhong
- Department of Pathology & Laboratory Medicine, Vancouver General Hospital, Vancouver
| | - T Ng
- Department of Pathology & Laboratory Medicine, Vancouver General Hospital, Vancouver
| | - D Ionescu
- Department of Pathology & Laboratory Medicine, BC Cancer Agency, Vancouver
| | - D F Schaeffer
- Department of Pathology & Laboratory Medicine, Vancouver General Hospital, Vancouver
| | - A J Mungall
- Canada's Michael Smith Genome Sciences Centre
| | - K L Mungall
- Canada's Michael Smith Genome Sciences Centre
| | - Y Zhao
- Canada's Michael Smith Genome Sciences Centre
| | - R A Moore
- Canada's Michael Smith Genome Sciences Centre
| | - Y Ma
- Canada's Michael Smith Genome Sciences Centre
| | - S Chia
- Division of Medical Oncology, BC Cancer Agency, Vancouver
| | - C Ho
- Division of Medical Oncology, BC Cancer Agency, Vancouver
| | - D J Renouf
- Division of Medical Oncology, BC Cancer Agency, Vancouver
| | - K Gelmon
- Division of Medical Oncology, BC Cancer Agency, Vancouver
| | - S J M Jones
- Canada's Michael Smith Genome Sciences Centre.,Department of Medical Genetics, University of British Columbia, Vancouver.,Department of Molecular Biology and Biochemistry, Simon Fraser University, Vancouver, Canada
| | - M A Marra
- Canada's Michael Smith Genome Sciences Centre.,Department of Medical Genetics, University of British Columbia, Vancouver
| | - J Laskin
- Division of Medical Oncology, BC Cancer Agency, Vancouver
| |
Collapse
|
93
|
Syed D, Waseem D, Dumas S, Fastner S, Hackett K, Ho C, Xu G, Ntambi J, Mukhtar H. 186 Stearoyl-CoA desaturase-5 is upregulated in basal cell carcinoma: A role in aberrant cell proliferation in human skin. J Invest Dermatol 2018. [DOI: 10.1016/j.jid.2018.03.191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
94
|
Liao F, Tsai W, Ho C, Chen J, Lin C. 0480 Rapid Eye Movement Period Apnea Contribute to Peripheral Arterial Stiffness in Obstructive Sleep Apnea Syndrome. Sleep 2018. [DOI: 10.1093/sleep/zsy061.479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- F Liao
- Sleep Medicine Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, TAIWAN
| | - W Tsai
- Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, TAIWAN
| | - C Ho
- Department of Adapted Physical Education, National Taiwan Sport University., Taoyuan, TAIWAN
| | - J Chen
- Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, TAIWAN
| | - C Lin
- Department of Otolaryngology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, TAIWAN
- Sleep Medicine Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, TAIWAN
| |
Collapse
|
95
|
Politi MC, George N, Li T, Korenblat KM, Fowler KJ, Ho C, Liapakis A, Roth D, Yee J. Project HELP: a study protocol to pilot test a shared decision-making tool about treatment options for patients with hepatitis C and chronic kidney disease. Pilot Feasibility Stud 2018; 4:55. [PMID: 29484199 PMCID: PMC5822614 DOI: 10.1186/s40814-018-0251-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2017] [Accepted: 02/14/2018] [Indexed: 02/08/2023] Open
Abstract
BACKGROUND Recent advances in treatment have given patients with chronic kidney disease (CKD) access to safer and more effective medications to treat comorbid hepatitis C virus (HCV) infection. Given the variety and complexity of treatment options that depend on patients' clinical characteristics and personal preferences, education and decision support are needed to prepare patients better to discuss treatment options with their clinicians. METHODS Drawing on International Patient Decision Aids Standards guidelines, literature reviews, and guidance from a diverse expert advisory group of nephrologists, hepatologists, and patients, we will develop and test a HCV and CKD decision support tool. Named Project HELP (Helping Empower Liver and kidney Patients), this tool will support patients with HCV and CKD during decisions about whether, when, and how to treat each illness. The tool will (1) explain information using plain language and graphics; (2) provide a step-by-step process for thinking about treating HCV and CKD; (3) tailor relevant information to each user by asking about the individual's stage of CKD, stage of fibrosis, prior treatment, and comorbidities; (4) assess user knowledge and values for treatment choices; and (5) help individuals use and consider information appropriate to their values and needs to discuss with a clinician. A pilot study including 70 individuals will evaluate the tool's efficacy, usability, and likelihood of using it in clinical practice. Eligibility criteria will include individuals who understand and read English, who are at least 18 years old, have a diagnosis of HCV (any genotype) and CKD (any stage), and are considering treatment options. DISCUSSION This study can identify particular characteristics of individuals or groups that might experience challenges initiating treatment for HCV in the CKD population. This tool could provide a resource to facilitate patient-clinician discussions regarding HCV and CKD treatment options.
Collapse
Affiliation(s)
- M. C. Politi
- Division of Public Health Sciences, Department of Surgery, Washington University in St. Louis School of Medicine, 660 S. Euclid Ave., Campus Box 8100, St. Louis, MO 63110 USA
| | - N. George
- Division of Public Health Sciences, Department of Surgery, Washington University in St. Louis School of Medicine, 660 S. Euclid Ave., Campus Box 8100, St. Louis, MO 63110 USA
| | - T. Li
- Department of Internal Medicine, Division of Nephrology, Washington University School of Medicine, 660 S. Euclid Ave., Campus Box 8129, St. Louis, MO 63110 USA
| | - K. M. Korenblat
- Department of Internal Medicine, Division of Gastroenterology, Washington University School of Medicine, 660 S. Euclid Ave., Campus Box 8124, St. Louis, MO 63110 USA
| | - K. J. Fowler
- The Voice of the Patient Inc., 908 South Cambridge Ave., Elmhurst, IL 60126 USA
| | - C. Ho
- California Pacific Medical Center, 2340 Clay Street, 3rd floor, San Francisco, CA 94115 USA
| | - A. Liapakis
- Department of Internal Medicine Section of Digestive Disease, Yale University School of Medicine, 333 Cedar St., PO Box 208019, New Haven, CT 06520 USA
| | - D. Roth
- Katz Family Division of Nephrology and Hypertension, University of Miami Miller School of Medicine, 120 NW 14th St. Room 813, Miami, FL 33136 USA
| | - J. Yee
- Division Head of Nephrology, Hypertension & Transplant, Henry Ford Hospital and Medical Center, 2799 West Grand Blvd, CFP-514, Detroit, MI 48202-2689 USA
| |
Collapse
|
96
|
Greenwell K, Hussain L, Ho C, Dunki-Jacobs E, Lee D, Bramlage M, Bills G, Mehta A, Jones J, Jackson A, Wexelman B. Abstract PD3-04: Complete pathologic response rate to neoadjuvant chemotherapy increases with increasing HER2 ratio in HER2 over-expressing breast cancer: Analysis of the National cancer database (NCDB). Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-pd3-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: HER2-positive (HER2+) breast cancer is an aggressive subtype that overexpresses human epidermal growth factor receptor 2 promoting cancer cell growth. Monoclonal antibodies targeting the HER2 receptor have improved survival for this patient population, and current NCCN guidelines recommend consideration of neoadjuvant anti-HER2 therapy (NAC) in Stage 2 & 3 HER2+ breast cancer. Pathologic complete response (pCR) to NAC has correlated with longer disease free survival in multiple trials.
Per ASCO-CAP guidelines tumors are considered HER2+ if HER2 copy number≥ 6/cell, HER2/CEP17 ratio≥ 2, or ratio<2 & HER2 copy number ≥6/cell. We hypothesize that patients with higher HER2 ratios will have higher rates of pCR after NAC.
Methods: The National Cancer Database is supported by the American College of Surgeons and the American Cancer Society containing de-identified patient treatment data from over 1,500 US facilities. We performed a retrospective review comparing pCR rates after NAC based on HER2 ratio. Patients were excluded if they were HER2 negative, did not undergo NAC, or if the HER2 ratio was not recorded. Chi-squared and Fisher's exact test were used to compare pCR versus partial response between deciles of HER2 ratios.
Results: The NCDB included 237,118 patients with HER2 equivocal or HER2+ breast tumors. 29,291 of these patients underwent NAC, and HER2 ratios were recorded in 14,597 of the NAC cases. The majority (98%) of included cases were from 2010-2014. A pCR was noted in 9,752 patients and 11,402 patients had a partial response. No response was observed in 1,735 patients and 6,402 patients had a response but the degree was not recorded.
HER2 ratios were significantly different between pCR vs. partial response groups, p <0.001. We identified a direct relationship between increasing HER2 ratio and response to NAC. For ratios 2-2.9, 23.6% achieved pCR and 44.7% had a partial response. For ratio of 5-5.9, 40.7% achieved pCR and even higher rates of pCR were noted for ratios 8-8.9; 49.5% achieved pCR. While both estrogen receptor (ER) positive and ER negative tumors demonstrated this trend, ER negative tumors had higher rates of pCR (ER negative pCR range 37.6% to 59.4% vs ER positive pCR range 16.9% to 42.3%, p<0.01).
Conclusion: Contrary to current dogma, not all HER2+ tumors respond similarly to NAC. We demonstrate a linear relationship between HER2 ratio and pCR in over 14,000 patients. Those with HER2 ratios ≥5.0 were more likely to achieve pCR compared to patients with ratio ≤4.9. The NCDB reflects current clinical practice across the country not restricted to confines of clinical trials, and in this population higher HER2 ratios are predictive of pCR after NAC.
Response to NAC by Her2 Ratio- Complete vs Partial Response Response to NAC p ValueHER2 Ratio Complete Response- pCR (N) Partial Response (N) 1.00- 1.99141819.5%343047.2%<0.01 2.00- 2.9951423.6%97444.7%<0.01 3.00- 3.9928328.7%41942.4%<0.01 4.00- 4.9926533.2%30638.2%<0.01 5.00- 5.9929940.7%24333.1%<0.01 6.00- 6.9929241.0%25435.5%<0.01 7.00- 7.9924746.2%17432.5%<0.01 8.00- 8.9918749.5%12132.0%<0.01 9.00- 9.87 and greater44143.9%31431.3%<0.01TOTAL 394627.0%623542.7%<0.01
Citation Format: Greenwell K, Hussain L, Ho C, Dunki-Jacobs E, Lee D, Bramlage M, Bills G, Mehta A, Jones J, Jackson A, Wexelman B. Complete pathologic response rate to neoadjuvant chemotherapy increases with increasing HER2 ratio in HER2 over-expressing breast cancer: Analysis of the National cancer database (NCDB) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD3-04.
Collapse
Affiliation(s)
- K Greenwell
- Trihealth Cancer Institute, Cincinnati, OH; Trihealth Hatton Research Institute, Cincinnati, OH; Trihealth, Cincinnati, OH
| | - L Hussain
- Trihealth Cancer Institute, Cincinnati, OH; Trihealth Hatton Research Institute, Cincinnati, OH; Trihealth, Cincinnati, OH
| | - C Ho
- Trihealth Cancer Institute, Cincinnati, OH; Trihealth Hatton Research Institute, Cincinnati, OH; Trihealth, Cincinnati, OH
| | - E Dunki-Jacobs
- Trihealth Cancer Institute, Cincinnati, OH; Trihealth Hatton Research Institute, Cincinnati, OH; Trihealth, Cincinnati, OH
| | - D Lee
- Trihealth Cancer Institute, Cincinnati, OH; Trihealth Hatton Research Institute, Cincinnati, OH; Trihealth, Cincinnati, OH
| | - M Bramlage
- Trihealth Cancer Institute, Cincinnati, OH; Trihealth Hatton Research Institute, Cincinnati, OH; Trihealth, Cincinnati, OH
| | - G Bills
- Trihealth Cancer Institute, Cincinnati, OH; Trihealth Hatton Research Institute, Cincinnati, OH; Trihealth, Cincinnati, OH
| | - A Mehta
- Trihealth Cancer Institute, Cincinnati, OH; Trihealth Hatton Research Institute, Cincinnati, OH; Trihealth, Cincinnati, OH
| | - J Jones
- Trihealth Cancer Institute, Cincinnati, OH; Trihealth Hatton Research Institute, Cincinnati, OH; Trihealth, Cincinnati, OH
| | - A Jackson
- Trihealth Cancer Institute, Cincinnati, OH; Trihealth Hatton Research Institute, Cincinnati, OH; Trihealth, Cincinnati, OH
| | - B Wexelman
- Trihealth Cancer Institute, Cincinnati, OH; Trihealth Hatton Research Institute, Cincinnati, OH; Trihealth, Cincinnati, OH
| |
Collapse
|
97
|
|
98
|
Lacroix-Poisson F, Benard F, Wilson D, Adam M, Yapp D, Ho C, Laskin J. P1.03-020 Detection of Hypoxia Using EF5 PET/CT in 10 Patients with Advanced NSCLC Receiving Chemotherapy with and without Bevacizumab. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.824] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
99
|
Liao B, Chiang C, Chen P, Shen Y, Chen W, Hung J, Rau K, Lai C, Chen C, Kuo Y, Tsai Y, Wu S, Lin C, Wei Y, Wu M, Tsao S, Tsao T, Ho C, Feng Y, Tsao C, Lin M, Chong I, Hsia T, Chu N, Chen Y, Yu C, Yang J. P2.07-027 Efficacy and Safety of Nivolumab Therapy for Advanced NSCLC in the Expanded Access Named Patient Program in Taiwan. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.11.086] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
100
|
Leung B, Naik H, Laskin J, Wu J, Mackenzie R, Bates A, Ho C. MA 04.02 Assessing the Psychosocial Needs of Newly Diagnosed NSCLC Patients: Identifying the Population Most At-Risk. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|